Literature DB >> 21104228

Polymorphisms of the peroxisome proliferator-activated receptor γ (PPARγ) gene are associated with osteoporosis.

T Harsløf1, C L Tofteng, L B Husted, M Nyegaard, A Børglum, M Carstens, L Stenkjær, K Brixen, P Eiken, J-E B Jensen, L Mosekilde, L Rejnmark, B L Langdahl.   

Abstract

UNLABELLED: Stimulation of PPARγ turns mesenchymal stem cells into adipocytes instead of osteoblasts. We investigated the effect of polymorphisms in the PPARγ gene on BMD and fracture risk in two Danish cohorts and found opposing effects of certain SNPs and haplotypes in the two cohorts probably owing to environmental factors.
INTRODUCTION: Stimulation of PPARγ causes development of mesenchymal stem cells to adipocytes instead of osteoblasts leading to decreased osteoblast number and BMD. The aim of this study was to examine the effect of PPARG polymorphisms on BMD and fracture risk in two Danish cohorts: AROS, a case-control population comprising 809 individuals and DOPS, a population comprising 1,716 perimenopausal women allocated to hormone therapy or not at baseline and followed for 10 years. On the basis of linkage disequilibrium between SNPs throughout the gene and previous studies we chose 10 polymorphisms for investigation.
METHODS: In AROS, individuals heterozygous for the polymorphisms rs12497191, rs4135263, and rs1151999 had an increased risk of vertebral fractures (OR = 1.48-1.76, p = 0.005-0.04) compared with individuals homozygous for the common allele. In DOPS, individuals heterozygous for rs1151999 had an increased BMD at the hip sites (p ≤ 0.02). An interaction between rs1151999 and diet was found on BMD in both cohorts.
RESULTS: For the polymorphism rs1152003 there was an interaction with body weight on BMD at all sites in both cohorts (p ≤ 0.07). Stratified analyses revealed that in the high weight group in AROS individuals homozygous for the variant allele had a decreased BMD (p ≤ 0.02), whereas the same pattern was found in the low weight group in DOPS (p ≤ 0.03). A number of haplotype associations were found as well, the direction of which was opposite in the two cohorts.
CONCLUSION: Our study suggests an association SNPs in PPARG and haplotypes thereof and BMD and fracture risk. The effect however appears to be modifiable by environmental factors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104228     DOI: 10.1007/s00198-010-1491-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  44 in total

1.  Determinants of bone mineral density in middle aged men: a population-based study.

Authors:  J Huuskonen; S B Väisänen; H Kröger; C Jurvelin; C Bouchard; E Alhava; R Rauramaa
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

2.  Genetic determinants of bone mass in adult women: a reevaluation of the twin model and the potential importance of gene interaction on heritability estimates.

Authors:  C W Slemenda; J C Christian; C J Williams; J A Norton; C C Johnston
Journal:  J Bone Miner Res       Date:  1991-06       Impact factor: 6.741

3.  Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.

Authors:  Xiang-Hang Luo; Li-Juan Guo; Hui Xie; Ling-Qing Yuan; Xian-Ping Wu; Hou-De Zhou; Er-Yuan Liao
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

4.  Patterns of association between PPARgamma genetic variation and indices of adiposity and insulin action in African-Americans and whites: the CARDIA Study.

Authors:  Qi Wei; David R Jacobs; Pamela J Schreiner; David S Siscovick; Michael W Steffes; Myriam Fornage
Journal:  J Mol Med (Berl)       Date:  2006-09-06       Impact factor: 4.599

5.  Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.

Authors:  M Alexandra Sorocéanu; Dengshun Miao; Xiu-Ying Bai; Hanyi Su; David Goltzman; Andrew C Karaplis
Journal:  J Endocrinol       Date:  2004-10       Impact factor: 4.286

6.  Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population.

Authors:  Aline Meirhaeghe; Michael W T Tanck; Lluis Fajas; Caroline Janot; Nicole Helbecque; Dominique Cottel; Johan Auwerx; Philippe Amouyel; Jean Dallongeville
Journal:  Mol Genet Metab       Date:  2005-06       Impact factor: 4.797

7.  PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter.

Authors:  L Fajas; J C Fruchart; J Auwerx
Journal:  FEBS Lett       Date:  1998-10-30       Impact factor: 4.124

8.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

9.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

Authors:  B M Forman; P Tontonoz; J Chen; R P Brun; B M Spiegelman; R M Evans
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

10.  A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians.

Authors:  Yunhua Li Muller; Clifton Bogardus; Brock A Beamer; Alan R Shuldiner; Leslie J Baier
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

View more
  8 in total

Review 1.  The genetics of bone loss: challenges and prospects.

Authors:  Braxton D Mitchell; Laura M Yerges-Armstrong
Journal:  J Clin Endocrinol Metab       Date:  2011-02-23       Impact factor: 5.958

2.  Osteoporosis genetics: year 2011 in review.

Authors:  David Karasik; Miri Cohen-Zinder
Journal:  Bonekey Rep       Date:  2012-08-01

Review 3.  PFAS and Potential Adverse Effects on Bone and Adipose Tissue Through Interactions With PPARγ.

Authors:  Andrea B Kirk; Stephani Michelsen-Correa; Cliff Rosen; Clyde F Martin; Bruce Blumberg
Journal:  Endocrinology       Date:  2021-12-01       Impact factor: 5.051

4.  Diet and gene interactions influence the skeletal response to polyunsaturated fatty acids.

Authors:  Nicolas Bonnet; Emmanuel Somm; Clifford J Rosen
Journal:  Bone       Date:  2014-08-01       Impact factor: 4.398

Review 5.  Impact of the environment on the skeleton: is it modulated by genetic factors?

Authors:  Cheryl L Ackert-Bicknell; David Karasik
Journal:  Curr Osteoporos Rep       Date:  2013-09       Impact factor: 5.096

6.  Effect of Salicornia herbacea on osteoblastogenesis and adipogenesis in vitro.

Authors:  Fatih Karadeniz; Jung-Ae Kim; Byul-Nim Ahn; Myeong Sook Kwon; Chang-Suk Kong
Journal:  Mar Drugs       Date:  2014-10-10       Impact factor: 5.118

Review 7.  Influence of the Periodontal Disease, the Most Prevalent Inflammatory Event, in Peroxisome Proliferator-Activated Receptors Linking Nutrition and Energy Metabolism.

Authors:  Lourdes Román-Malo; Pedro Bullon
Journal:  Int J Mol Sci       Date:  2017-07-05       Impact factor: 5.923

8.  Simvastatin inhibits the adipogenesis of bone marrow‑derived mesenchymal stem cells through the downregulation of chemerin/CMKLR1 signaling.

Authors:  Yao Guo; Jianzhong Huo; Dou Wu; Haihu Hao; Xinghua Ji; Enzhe Zhao; Boyuan Nie; Qiang Liu
Journal:  Int J Mol Med       Date:  2020-05-18       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.